Alborz Yazdi
Fondateur chez Exavir Therapeutics
Postes actifs de Alborz Yazdi
Sociétés | Poste | Début | Fin |
---|---|---|---|
Exavir Therapeutics
Exavir Therapeutics Miscellaneous Commercial ServicesCommercial Services Exavir Therapeutics is an American preclinical stage biotechnology company founded by Alborz Yazdi, Howard E. Gendelman, Benson Edagwa, dedicated to developing ultra-long-acting therapeutics for patients with chronic viral infections and central nervous system disorders. The company's pipeline includes several long-acting antiviral nanomedicines as well as an earlier stage HIV cure program that utilizes CRISPR nucleases and proprietary LNP formulations to precisely deliver pro-viral DNA excision payloads to tissues that are the target of HIV. The company aims to eliminate HIV and other viral infections with a broad modality-agnostic approach, beginning with long-acting antiviral therapeutics. HIV is one of the world's most serious public health challenges, and Exavir Therapeutics is developing ultra-long-acting nanomedicines for HIV, other viral infections, and CNS disorders. | Fondateur | - | - |
President | - | - |
Historique de carrière de Alborz Yazdi
Anciens postes connus de Alborz Yazdi
Sociétés | Poste | Début | Fin |
---|---|---|---|
Passaic Capital Management LLC
Passaic Capital Management LLC Investment ManagersFinance Passaic Capital Management LLC (Passaic Capital) is an alternative investment firm headquartered in Albany, New York. The firm was founded in 2013 as a hedge fund platform of Millennium Management LLC. Passaic Capital manages a long/short equity portfolio for high net worth investors. | Analyst-Equity | 01/10/2020 | 01/02/2022 |
Bain Capital Life Sciences LP
Bain Capital Life Sciences LP Investment ManagersFinance Bain Capital Life Sciences LP (Bain Capital Life Sciences) is a private equity subsidiary of Bain Capital Private Equity LP, ultimately held by Bain Capital Holdings LP, founded in 2016. The firm is headquartered in Boston, Massachusetts. | Analyste en capital-investissement | 01/01/2019 | 01/10/2020 |
Formation de Alborz Yazdi
Yale University | Undergraduate Degree |
Statistiques
Internationale
Etats-Unis | 5 |
Opérationnelle
Private Equity Analyst | 1 |
Undergraduate Degree | 1 |
Analyst-Equity | 1 |
Sectorielle
Finance | 3 |
Consumer Services | 2 |
Commercial Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 3 |
---|---|
Bain Capital Life Sciences LP
Bain Capital Life Sciences LP Investment ManagersFinance Bain Capital Life Sciences LP (Bain Capital Life Sciences) is a private equity subsidiary of Bain Capital Private Equity LP, ultimately held by Bain Capital Holdings LP, founded in 2016. The firm is headquartered in Boston, Massachusetts. | Finance |
Passaic Capital Management LLC
Passaic Capital Management LLC Investment ManagersFinance Passaic Capital Management LLC (Passaic Capital) is an alternative investment firm headquartered in Albany, New York. The firm was founded in 2013 as a hedge fund platform of Millennium Management LLC. Passaic Capital manages a long/short equity portfolio for high net worth investors. | Finance |
Exavir Therapeutics
Exavir Therapeutics Miscellaneous Commercial ServicesCommercial Services Exavir Therapeutics is an American preclinical stage biotechnology company founded by Alborz Yazdi, Howard E. Gendelman, Benson Edagwa, dedicated to developing ultra-long-acting therapeutics for patients with chronic viral infections and central nervous system disorders. The company's pipeline includes several long-acting antiviral nanomedicines as well as an earlier stage HIV cure program that utilizes CRISPR nucleases and proprietary LNP formulations to precisely deliver pro-viral DNA excision payloads to tissues that are the target of HIV. The company aims to eliminate HIV and other viral infections with a broad modality-agnostic approach, beginning with long-acting antiviral therapeutics. HIV is one of the world's most serious public health challenges, and Exavir Therapeutics is developing ultra-long-acting nanomedicines for HIV, other viral infections, and CNS disorders. | Commercial Services |
- Bourse
- Insiders
- Alborz Yazdi
- Expérience